In a bold move that’s set to shake up the beauty and skincare industry, L’Oréal is doubling down on its investment in Galderma, signaling a major shift in its strategy toward skincare drugs. But here’s where it gets controversial: is this a game-changer for the cosmetics giant, or a risky bet in an already crowded market?
On December 8, 2025, L’Oréal SA announced it would double its stake in Galderma Group AG to a significant 20%, marking a substantial commitment to the skincare and pharmaceutical sectors. This strategic decision comes as the French beauty powerhouse aims to strengthen its position in a market where the lines between cosmetics and medical skincare are increasingly blurring. The deal involves acquiring 24 million shares from an investor group led by private equity firm EQT AB, though the financial details of the transaction remain undisclosed, leaving industry analysts and observers speculating about the valuation and long-term implications.
And this is the part most people miss: As part of the agreement, Galderma is expected to appoint two L’Oréal representatives to its board, replacing directors from the EQT group. This move not only solidifies L’Oréal’s influence over Galderma’s strategic direction but also raises questions about how the cosmetics giant will navigate the complexities of the pharmaceutical industry. Will L’Oréal’s expertise in beauty translate seamlessly into skincare drugs, or will it face challenges in this highly regulated and scientifically driven field?
For beginners, it’s important to understand that Galderma is a leader in dermatological solutions, offering products that range from acne treatments to anti-aging therapies. L’Oréal’s increased stake in the company reflects a broader trend in the beauty industry, where companies are investing heavily in science-backed skincare to meet consumer demand for effective, results-driven products. However, this shift also comes with risks, as pharmaceutical development is costly and time-consuming, with no guarantee of success.
Here’s a thought-provoking question for you: Is L’Oréal’s move a visionary step toward dominating the future of skincare, or is it spreading itself too thin in an attempt to stay relevant? Let us know your thoughts in the comments below. As the beauty and pharmaceutical industries continue to converge, one thing is clear: L’Oréal is not just playing the game—it’s rewriting the rules.
